Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
We identified not only known AEs, but also new AE signals such as movement disorder. However, signals does not reveal actual risk, prospective clinical trials are still required to verify their causal connection.
Authors
- Qing Shan (ORCID: https://orcid.org/0009-0002-7473-2493)
- Jiao Qian (ORCID: https://orcid.org/0000-0003-3497-2310)
- Y. Zhang (ORCID: https://orcid.org/0009-0000-1308-159X)
- Jin‐Min Guo (ORCID: https://orcid.org/0000-0001-5737-7384)
- Yan Chen (ORCID: https://orcid.org/0000-0002-1125-313X)
- Bing Li (ORCID: https://orcid.org/0000-0001-8958-2972)
- Mingyang Qian
Institutions
- Weifang Medical University (CN)
- Second Military Medical University (CN)
- Changhai Hospital (CN)
- 82th Hospital of Pla (CN)
- 458th Hospital PLA (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1080/14740338.2025.2468855
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.61